Transcriptional changes in peanut-specific CD4+ T cells over the course of oral immunotherapy

Copyright © 2020 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 219(2020) vom: 15. Okt., Seite 108568
1. Verfasser: Wang, Weiqi (VerfasserIn)
Weitere Verfasser: Lyu, Shu-Chen, Ji, Xuhuai, Gupta, Sheena, Manohar, Monali, Dhondalay, Gopal K R, Chinthrajah, Sharon, Andorf, Sandra, Boyd, Scott D, Tibshirani, Robert, Galli, Stephen J, Nadeau, Kari C, Maecker, Holden T
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2020
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Clinical Trial, Phase II Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural CD4+ T cell Food allergy OIT Peanut allergy RNAseq Single cell mehr... Allergens TGFB1 protein, human Transforming Growth Factor beta1
LEADER 01000naa a22002652 4500
001 NLM313586950
003 DE-627
005 20231225150908.0
007 cr uuu---uuuuu
008 231225s2020 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2020.108568  |2 doi 
028 5 2 |a pubmed24n1045.xml 
035 |a (DE-627)NLM313586950 
035 |a (NLM)32783912 
035 |a (PII)S1521-6616(20)30728-2 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Wang, Weiqi  |e verfasserin  |4 aut 
245 1 0 |a Transcriptional changes in peanut-specific CD4+ T cells over the course of oral immunotherapy 
264 1 |c 2020 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 17.05.2021 
500 |a Date Revised 02.10.2021 
500 |a published: Print-Electronic 
500 |a ClinicalTrials.gov: NCT02103270 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2020 Elsevier Inc. All rights reserved. 
520 |a Oral immunotherapy (OIT) can successfully desensitize allergic individuals to offending foods such as peanut. Our recent clinical trial (NCT02103270) of peanut OIT allowed us to monitor peanut-specific CD4+ T cells, using MHC-peptide Dextramers, over the course of OIT. We used a single-cell targeted RNAseq assay to analyze these cells at 0, 12, 24, 52, and 104 weeks of OIT. We found a transient increase in TGFβ-producing cells at 52 weeks in those with successful desensitization, which lasted until 117 weeks. We also performed clustering and identified 5 major clusters of Dextramer+ cells, which we tracked over time. One of these clusters appeared to be anergic, while another was consistent with recently described TFH13 cells. The other 3 clusters appeared to be Th2 cells by their coordinated production of IL-4 and IL-13, but they varied in their expression of STAT signaling proteins and other markers. A cluster with high expression of STAT family members also showed a possible transient increase at week 24 in those with successful desensitization. Single cell TCRαβ repertoire sequences were too diverse to track clones over time. Together with increased TGFβ production, these changes may be mechanistic predictors of successful OIT that should be further investigated 
650 4 |a Clinical Trial, Phase II 
650 4 |a Journal Article 
650 4 |a Randomized Controlled Trial 
650 4 |a Research Support, N.I.H., Extramural 
650 4 |a CD4+ T cell 
650 4 |a Food allergy 
650 4 |a OIT 
650 4 |a Peanut allergy 
650 4 |a RNAseq 
650 4 |a Single cell 
650 7 |a Allergens  |2 NLM 
650 7 |a TGFB1 protein, human  |2 NLM 
650 7 |a Transforming Growth Factor beta1  |2 NLM 
700 1 |a Lyu, Shu-Chen  |e verfasserin  |4 aut 
700 1 |a Ji, Xuhuai  |e verfasserin  |4 aut 
700 1 |a Gupta, Sheena  |e verfasserin  |4 aut 
700 1 |a Manohar, Monali  |e verfasserin  |4 aut 
700 1 |a Dhondalay, Gopal K R  |e verfasserin  |4 aut 
700 1 |a Chinthrajah, Sharon  |e verfasserin  |4 aut 
700 1 |a Andorf, Sandra  |e verfasserin  |4 aut 
700 1 |a Boyd, Scott D  |e verfasserin  |4 aut 
700 1 |a Tibshirani, Robert  |e verfasserin  |4 aut 
700 1 |a Galli, Stephen J  |e verfasserin  |4 aut 
700 1 |a Nadeau, Kari C  |e verfasserin  |4 aut 
700 1 |a Maecker, Holden T  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 219(2020) vom: 15. Okt., Seite 108568  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:219  |g year:2020  |g day:15  |g month:10  |g pages:108568 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2020.108568  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 219  |j 2020  |b 15  |c 10  |h 108568